By the mid-1990s, the Society had experienced significant changes and growth, including a new constitution and bylaws, a newly established scientific structure, and many enhancements in the Annual Meeting. A new generation of leadership had emerged that had only known the post-merger Society. In 1998, the first ASCPT strategic plan was created under the leadership of Carl Peck, MD, and ASCPT again found itself going through a variety of changes including:
- In 1999, Sharon Swan, CAE, FASAE, was named Executive Director and moved the Society’s office to the Washington D.C. area to enhance communications, involvement, and visibility. The ASCPT office was later purchased in September 2003 and has since undergone extensive renovations to accommodate the growing needs of the Society.
- ASCPT purchased Clinical Pharmacology & Therapeutics in 2001, and in 2006, Scott A. Waldman, MD, PhD, was selected as Editor-in-Chief of the journal. Under Dr. Waldman’s leadership, the journal transitioned to publisher John Wiley & Sons, selected a new editorial team and added new content and color to the journal.
- In 2012 ASCPT launched the online only Open Access journal CPT: Pharmacometrics & Systems Pharmacology under the leadership of Editor-in-Chief, Piet H. van der Graaf, PhD, PharmD.
- In January 2016 ASCPT began publishing the online only Open Access Clinical and Translational Science as part of its publication family under the leadership of Editor-in-Chief, John A. Wagner, MD, PhD.
A new 2015-2020 Strategic Plan is in place that focuses on the five strategic goals of leadership, influence, outreach, science, and education. ASCPT’s program structure is dynamic, ambitious and field-tested. Its leadership is vibrant and open to new ideas and spheres of influence. The Society’s membership grows yearly and is increasingly diversified. The Society continues to grow internationally as well as within the United States.